Cillian Clancy1, John P Burke, J Calvin Coffey. 1. Department of Colorectal Surgery, University Hospital Limerick, Graduate Entry Medical School, University of Limerick, Ireland.
Abstract
INTRODUCTION: The current management of locally advanced rectal cancer involves total mesorectal excision, which may be preceded by neo-adjuvant chemoradiotherapy (CRT). Individual patient response to CRT is variable and reproducible biomarkers of response are needed. The role of the V-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) in rectal cancer remains equivocal. The aim of the current study was to systematically appraise the effect of KRAS mutation on outcomes following CRT for rectal cancer. METHODS: A comprehensive search for published studies examining the effect of KRAS mutation on outcome after neo-adjuvant CRT in rectal cancer was performed. Each study was reviewed and data extracted. Random-effects methods were used to combine data. RESULTS: Data was retrieved from 8 series describing 696 patients. Neo-adjuvant treatment regimens varied in usage of chemotherapeutic agents and interval to surgery. KRAS mutation was present in an average of 33.2 ± 11.8% of patients with rectal cancer. KRAS mutation was not associated with decreased rates of pathological complete response (odds ratio (OR): 0.778, 95% confidence interval (CI): 0.424-1.428, P = 0.418), tumor down-staging (OR: 0.846, 95% CI: 0.331-2.162, P = 0.728) or an increase in cancer related mortality (OR: 1.239, 95% CI: 0.607-2.531, P = 0.555). CONCLUSIONS: Based on these data, the presence of KRAS mutation does not affect tumor down-staging or cancer specific survival following neo-adjuvant CRT and surgery for rectal cancer.
INTRODUCTION: The current management of locally advanced rectal cancer involves total mesorectal excision, which may be preceded by neo-adjuvant chemoradiotherapy (CRT). Individual patient response to CRT is variable and reproducible biomarkers of response are needed. The role of the V-Ki-ras2 Kirsten ratsarcoma viral oncogene (KRAS) in rectal cancer remains equivocal. The aim of the current study was to systematically appraise the effect of KRAS mutation on outcomes following CRT for rectal cancer. METHODS: A comprehensive search for published studies examining the effect of KRAS mutation on outcome after neo-adjuvant CRT in rectal cancer was performed. Each study was reviewed and data extracted. Random-effects methods were used to combine data. RESULTS: Data was retrieved from 8 series describing 696 patients. Neo-adjuvant treatment regimens varied in usage of chemotherapeutic agents and interval to surgery. KRAS mutation was present in an average of 33.2 ± 11.8% of patients with rectal cancer. KRAS mutation was not associated with decreased rates of pathological complete response (odds ratio (OR): 0.778, 95% confidence interval (CI): 0.424-1.428, P = 0.418), tumor down-staging (OR: 0.846, 95% CI: 0.331-2.162, P = 0.728) or an increase in cancer related mortality (OR: 1.239, 95% CI: 0.607-2.531, P = 0.555). CONCLUSIONS: Based on these data, the presence of KRAS mutation does not affect tumor down-staging or cancer specific survival following neo-adjuvant CRT and surgery for rectal cancer.
Authors: A Sebio; J Salazar; D Páez; A Berenguer-Llergo; E Del Río; M Tobeña; M Martín-Richard; I Sullivan; E Targarona; J Balart; M Baiget; A Barnadas Journal: Pharmacogenomics J Date: 2014-07-15 Impact factor: 3.550
Authors: Ian S Reynolds; Aobhlinn O'Toole; Joseph Deasy; Deborah A McNamara; John P Burke Journal: Int J Colorectal Dis Date: 2017-01-11 Impact factor: 2.571
Authors: Pierre Lovinfosse; Marc Polus; Daniel Van Daele; Philippe Martinive; Frédéric Daenen; Mathieu Hatt; Dimitris Visvikis; Benjamin Koopmansch; Frédéric Lambert; Carla Coimbra; Laurence Seidel; Adelin Albert; Philippe Delvenne; Roland Hustinx Journal: Eur J Nucl Med Mol Imaging Date: 2017-10-18 Impact factor: 9.236
Authors: Kasun Wanigasooriya; Joao D Barros-Silva; Louise Tee; Mohammed E El-Asrag; Agata Stodolna; Oliver J Pickles; Joanne Stockton; Claire Bryer; Rachel Hoare; Celina M Whalley; Robert Tyler; Toritseju Sillo; Christopher Yau; Tariq Ismail; Andrew D Beggs Journal: Front Oncol Date: 2022-07-04 Impact factor: 5.738
Authors: Oliver S Chow; Deborah Kuk; Metin Keskin; J Joshua Smith; Niedzica Camacho; Raphael Pelossof; Chin-Tung Chen; Zhenbin Chen; Karin Avila; Martin R Weiser; Michael F Berger; Sujata Patil; Emily Bergsland; Julio Garcia-Aguilar Journal: Ann Surg Oncol Date: 2016-03-28 Impact factor: 5.344
Authors: Jeong Won Lee; Jong Hoon Lee; Byoung Yong Shim; Sung Hwan Kim; Mi-Joo Chung; Bong-Hyeon Kye; Hyung Jin Kim; Hyeon Min Cho; Hong Seok Jang Journal: Medicine (Baltimore) Date: 2015-08 Impact factor: 1.889